Clinical development programs employing monoclonal antibodies specific for either folate receptor alpha in certain cancers of epithelial origin, including EOC, and folate receptor beta in inflammatory disorders such as arthritis, are underway. This evidence concerns the gene FOLR1 and arthritic joint disease.